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Objective: We wanted to evaluate the feasibility of catheter-directed thrombolysis with a continuous infusion of low-dose 
urokinase for treating non-acute (less than 14 days) deep venous thrombosis of the lower extremity.
Materials and Methods: The clinical data of 110 patients who were treated by catheter-directed thrombolysis with 
a continuous infusion of low-dose urokinase for lower extremity deep venous thrombosis was analysed. Adjunctive 
angioplasty or/and stenting was performed for the residual stenosis. Venous recanalization was graded by pre- and post-
treatment venography. Follow-up was performed by clinical evaluation and Doppler ultrasound. 
Results: A total of 112 limbs with deep venous thrombosis with a mean symptom duration of 22.7 days (range: 15-38 
days) were treated with a urokinase infusion (mean: 3.5 million IU) for a mean of 196 hours. After thrombolysis, stent 
placement was performed in 25 iliac vein lesions and percutaneous angioplasty (PTA) alone was done in fi  ve iliac veins. 
Clinically signifi  cant recanalization was achieved in 81% (90 of 112) of the treated limbs; complete recanalization was 
achieved in 28% (31 of 112) and partial recanalization was achieved in 53% (59 of 112). Minor bleeding occurred in 14 
(13%) patients, but none of the patients suffered from major bleeding or symptomatic pulmonary embolism. During follow-
up (mean: 15.2 months, range: 3-24 months), the veins were patent in 74 (67%) limbs. Thirty seven limbs (32%) showed 
progression of the stenosis with luminal narrowing more than 50%, including three with rethrombosis, while one revealed 
an asymptomatic iliac vein occlusion; 25 limbs (22%) developed mild post-thrombotic syndrome, and none had severe 
post-thrombotic syndrome. Valvular refl  ux occurred in 24 (21%) limbs. 
Conclusion: Catheter-directed thrombolysis with a continuous infusion of low-dose urokinase combined with adjunctive 
iliac vein stenting is safe and effective for removal of the clot burden and for restoration of the venous fl  ow in patients 
with non-acute lower extremity deep venous thrombosis.
Index terms: Non-acute lower extremity deep venous thrombosis; Catheter-directed thrombolysis; Stent placement; Bleeding 
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INTRODUCTION
Treatment of non-acute (a symptom duration greater 
than 14 days) deep vein thrombosis (DVT) has long been 
a clinical problem. Because the thrombus has a tendency 
to adhere and organize after the acute stage, it is more 
diffi  cult to dissolve and it often requires a longer time 
to be penetrated, and systemic thrombolysis is generally 
disappointing.
Catheter-directed thrombolysis (CDT) has the potential 
to improve the long-term outcomes in patients with DVT 
(1, 2). But the current CDT therapy is characterized by Korean J Radiol 12(1), Jan/Feb 2011 www.kjronline.org 98
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of lower extremity swelling and/or pain, a duration of 
symptoms beyond 14 days and they were positive for 
D-dimer. The exclusion criteria were isolated infrapopliteal 
DVT, recurrent ipsilateral DVT, pre-existing leg ulcers 
or signs of chronic venous insuffi  ciency, a short life 
expectancy and contraindications to the use of contrast 
media, anticoagulation or thrombolytic agents. The 
contraindications to thrombolytic agents included active 
internal bleeding, recent cerebrovascular accident, recent 
serious trauma, recent major surgery (less than 2 weeks), 
allergy to thrombolytic agents, recent gastrointestinal 
bleeding, uncontrolled hypertension, pregnancy, bacterial 
endocarditis and coagulopathy. The study protocol was 
approved by the local ethics committee (China).
Treatment Procedure 
With the patient in the prone position, venous access 
was obtained through the ipsilateral popliteal vein under 
ultrasound guidance. A 5-Fr vascular sheath (Terumo, 
Japan) was placed and direct venography was performed 
to estimate the severity and extent of the DVT under 
fl  uoroscopy. A 5-Fr multiple-side-hole lysis catheter 
(AngioDynamics, Queensbury, NY) was then gently inserted 
with the tip embedded in the distal extent of the thrombus, 
and the catheter and sheath were fi  xed and joined with a 
an initial bolus or pulse-spray injection of a high-dose 
thrombolytic agent followed by continuous infusion during 
a short time (3), and this type of therapy is suggested for 
treating acute DVT (≤ 14 days) (4). This therapy also has 
a potentially higher incidence of major bleeding (8%) (5). 
As a result, treatment of non-acute DVT can cause a woeful 
predicament. 
In this study, we aimed at exploring a safe and effective 
therapy for non-acute DVT. We utilized CDT via the popliteal 
vein with a continuous infusion of low-dose urokinase for a 
longer time to treat selected non-acute lower extremity DVT, 
and this was combined with percutaneous angioplasty (PTA) 
and stent placement for an underlying venous stenosis or 
occlusion.
SUBJECTS AND METHODS
Patients Inclusion/Exclusion Criteria
Between December 2002 and February 2008, the 
consecutive patients who had a fi  rst episode of proximal 
DVT and who underwent CDT were included for this 
prospective study. The diagnosis of DVT was confi  rmed by 
the characteristic clinical manifestations and the Doppler 
ultrasound and/or venographic fi  ndings. The patients who 
were eligible for enrollment had documented symptoms 
ABCD
Fig. 1. Complete lysis in 33-year-old woman with 3-week history of swelling of left leg after cesarean section (venograms with 
patient in prone position). 
A-D. Venograms obtained before catheter-directed thrombolysis show part or complete absence of contrast material in superfi  cial femoral vein, 
common femoral vein, external iliac vein and common iliac vein. Korean J Radiol 12(1), Jan/Feb 2011 www.kjronline.org 99
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microinjection pump. Urokinase (Tianjin Biochem Pharma 
Co., LTD, China) was continuously pumped in at a low dose 
of 50,000-100,000 IU/8 hours (it was constituted in 50 ml 
of 0.9% saline) through the catheter with the same dose 
of urokinase being simultaneously pumped through the 
sheath. Surveillance venography was performed every 2-3 
days to access the degree of thrombolysis and to adjust the 
catheter position to facilitate effective thrombolysis. The 
fi  brinogen level was monitored at varying intervals, and if 
the fi  brinogen level dropped below 100 mg/dL, then further 
urokinase infusion was postponed to allow the fi  brinogen 
to recover, and then the urokinase infusion was restarted 
at 50% of the original dose. After thrombolysis, further 
adjunctive procedures were done if there was an underlying 
iliac vein stenosis of greater than 50%. The adjunctive 
procedures consisted of PTA and stent placement. Before 
catheterization, we recommended prophylactic placement 
of a retrievable inferior vena cava (IVC) fi  lter under 
local anesthesia through the right jugular vein or the 
contralateral femoral vein, and especially when patients 
had symptomatic pulmonary embolism, or the thrombus 
was free-fl  oating or it had propagated into the IVC. If there 
were large amounts of thrombus in the iliac vein before 
PTA, then placing an IVC fi  lter was recommended (6). In 
general, the IVC fi  lter was removed within two weeks after 
the placement.
In the hospital, low molecular weight heparin (LMWH; 
Fraxiparine, Glaxo Smith Kline, Suzhou, China) was 
administered subcutaneously at the rate of 0.4-0.6 ml for 
12 hours initially before CDT. Warfarin sodium (QILU Pharma 
Co., Ji’nan, China) was routinely started prior to hospital 
discharge and this was continued for at least six months, 
and the dose was adjusted to maintain an international 
EFGH
Fig. 1. Complete lysis in 33-year-old woman with 3-week history of swelling of left leg after 
cesarean section (venograms with patient in prone position). 
E-I. Venograms obtained after 240 hours of catheter-directed thrombolysis show deep veins (from superfi  cial 
femoral vein to external iliac vein) with restored patency; (G) complete occlusion in proximal segment of 
common iliac vein; (H) common iliac vein received percutaneous angioplasty and (I) common iliac vein has 
restored patency after percutaneous angioplasty.
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B C A
Fig. 2. Complete lysis in 26-year-old man with 16 days history of pain and swelling of both legs. 
A-C. Venograms were obtained with patient in prone position, and these are the images shown. Venogram obtained before catheter-directed 
thrombolysis shows complete occlusion of dual iliac veins (A). Venograms obtained after 192 hours of catheter-directed thrombolysis show 
complete lysis (B) in right iliac vein and (C) in left iliac vein.
B C A
Fig. 3. Iliac vein’s restored patency after catheter-directed thrombolysis and percutaneous angioplasty with stenting in 53-year-
old man who presented with edema of left lower extremity for 35 days. 
A-C. Images were taken with patient prone on angiography table and these are images shown. Before catheter-directed thrombolysis, note severe 
left common iliac vein stenosis (arrow), complete absence of contrast material in external iliac vein (curved arrows) and thrombosis in inferior 
vena cava (open arrows) (A). After 196 hours of catheter-directed thrombolysis, thrombus in inferior vena cava was completely dissolved and 
external iliac vein obtained complete patency (B), and common iliac vein stenosis was treated with stent placement (arrow) and then common 
iliac vein achieved complete patency (C).Korean J Radiol 12(1), Jan/Feb 2011 www.kjronline.org 101
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normalized ratio (INR) of 2.0 to 3.0. The LMWH was 
discontinued when the INR reached the target value for 
two consecutive days and the patients had received it for 
at least fi  ve days. After hospital discharge, all the patients 
were recommended to wear gradual compression stockings 
(below-knee, 30-40 mmHg, Sigvaris Inc., Peachtree City, 
GA) for more than one year.
During the treatment, we recorded the affected limbs’ 
circumference and the peri-procedure complications. We 
measured the thigh circumference at 15 cm above the 
knee joint and that of the calf at 10 cm below the tibial 
tuberosity. Complications were classifi  ed by the outcome 
with using the SIR (Society of Interventional Radiology) 
classifi  cation system for complications (7, 8). 
Assessment of Venous Recanalization 
The venograms were retrospectively reviewed by a 
consultant physician who was ‘blinded’ to the study’s 
purpose. Venous recanalization was determined by 
comparing the thrombus scores (9) of the pre- and post-
treatment venography, and this was categorized as follows: 
“complete” recanalization for 95-100% restoration of 
patency, “partial” for 50-95% and “minimal” for less than 
50% due to residual stenosis or organized thrombus (10, 
11). The recanalization was calculated after completion 
of treatment, which included the CDT and any additional 
adjunctive procedures. 
Defi  nitions and Follow-Up 
Technical success was defi  ned as restoration of patency 
and fl  ow with less than 50% residual stenosis, and clinical 
success was defi  ned as signifi  cant resolution of lower 
extremity pain and swelling. Follow-up visits were scheduled 
at three and six months, and every six months thereafter. 
At each visit, a patient underwent a clinical evaluation 
according to a modifi  ed Villalta scale (12), and a Doppler 
ultrasound assessment of the affected venous patency and 
refl  ux by a designated experienced vascular ultrasound 
physician. The presence of fi  ve leg symptoms (pain, cramps, 
heaviness, pruritus and paresthesia) and six objective signs 
(pretibial edema, skin induration, hyperpigmentation, new 
venous ectasia, redness and pain during calf compression) 
was scored. Each of the signs and symptoms were rated as 
0 (absent), 1 (mild), 2 (moderate) or 3 (severe). Clinical 
A B 
Fig. 4. Well-developed venous 
collaterals around recanalized 
femoral vein in 68-year-old man who 
presented with swelling of left leg for 
30 days.
A. Before catheter-directed thrombolysis, 
common femoral vein was completely 
occluded and there was small number of 
venous collaterals around it. B. After 216 
hours of catheter-directed thrombolysis, 
common femoral vein’s patency was 
restored and large number of venous 
collaterals opened around it.Korean J Radiol 12(1), Jan/Feb 2011 www.kjronline.org 102
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evaluation outcomes were classifi  ed as follows: a total 
score greater than 14 points or a venous ulcer was defi  ned 
as severe post-thrombotic syndrome (PTS); 5-14 points 
was given for mild PTS and less than fi  ve points was given 
for no PTS. Valvular refl  ux is defi  ned as greater than 0.5 
seconds for the valve closure time after distal compression 
and release using an ultrasonic probe in a non-weight-
bearing limb with the patient in the standing position (13). 
Primary patency was defi  ned as confi  rmed patency and 
< 50% restenosis as documented by Doppler ultrasound (14).
RESULTS
Patients
Of the 142 eligible patients with an episode of non-acute 
proximal DVT of the lower extremity, 32 were excluded 
because of previous ipsilateral DVT (n = 8), pre-existing 
leg ulcers or venous insuffi  ciency (n = 13), a poor life 
expectancy (n = 5) or the inability to attend follow-up 
visits (n = 6). The remaining 110 patients were enrolled 
this study. The baseline characteristics are reported in 
Table 1. Written informed consent was obtained from each 
enrolled patient or the family after the purpose and risk of 
the treatment were fully explained.
Assessment of Venous Recanalization
As determined at venography, iliofemoral DVT was present 
in 94 (84%) of 112 limbs and among these four (4%) limbs 
had thrombus propagating into the IVC, and femoropopliteal 
DVT occurred in 18 (16%) limbs. Eighty-two patients 
received retrieval IVC fi  lter placement (32 OptEase Filters, 
Cordis, Miami, FL; 50 Aegis Filters, Seercare, Shenzhen, 
China). After lysis, 63 fi  lters were retrieved (no evidence 
of clot was observed within the fi  lters) and the other 19 
were implanted permanently (fi  lling defects were observed 
within six fi  lters and the other 13 were abandoned and 
not retrieving due to economic considerations). Urokinase 
infusion was postponed and the dosage was adjusted in 
seven patients due to the fi  brinogen progressively dropping 
below 100 mg/dL. The mean duration of CDT was 196 
hours (range: 96-272 hours) and the average total dose of 
urokinase was 3.5 million IU (range: 1.8-5.7 million IU). 
Percutaneous angioplasty with stent placement (Wallstent, 
Boston Scientifi  c Co., Natick, MA) was necessary to 
treat residual stenoses and/or short occlusions in the 
iliac segments that were resistant to CDT in 25 (22%) 
limbs, and another fi  ve received iliac vein PTA alone for 
economic reasons. After completion of treatment, complete 
recanalization was achieved in 31 (28%) infusions and 
partial recanalization was achieved in 59 (53%), while 
Table 2. Change of Affected Limb Circumference Pre- and Post-Treatment (n = 112) 
Measurement Location*
Affected Limb Circumference (mean ± SD, cm)
Difference (mean ± SD, cm)
Pre-Treatment Post-Treatment
Thigh  6.3 ± 2.6 2.3 ± 1.5 4.0 ± 1.6
Calf  4.7 ± 2.2 1.4 ± 0.9 3.6 ± 1.8
Note.— *Thigh circumference was assessed at 15 cm above knee joint and calf circumference was assessed at 10 cm below tibial 
tuberosity.
Table 1. Patients’ Baseline Characteristics (112 Limbs in 
110 patients)
Variable Value 
Age, years (mean, range)  40.6 (29-70) 
Gender 
  Female  62 (56%)
  Male 48 (44%)
Symptom duration, days (mean, range)  22.7 (15-38)
Affected limb
  Left  94 (85%) 
  Right  14 (13%)
  Bilateral 2 (2%)
Thrombosis location 
  Iliofemoral  94 (84%)
  Femoropopliteal  18 (16%)
Risk factors 
  Postpartum  7 (6%)
  Postoperation  18 (16%)
  Trauma/fracture  24 (22%)
  Prolonged immobilization  7 (7%)
  Malignancy  1 (1%) 
  Percutaneous procedure  1 (1%)
  Idiopathic deep vein thrombosis  52 (47%)Korean J Radiol 12(1), Jan/Feb 2011 www.kjronline.org 103
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minimal recanalization was achieved in 22 (19%). Thus, 
90 (81%) treated limbs achieved signifi  cant recanalization 
(≥ 50% recanalization). In addition, venography indicated 
well-developed venous collaterals around the partially 
recanalized veins. Figures 1-4 illustrate the representative 
cases. 
At discharge from hospital, considerable improvement of 
the swelling and pain of the affected limb was achieved 
in 96% (108 of 112) of the limbs. The thigh circumference 
of the affected limb decreased by 4.0 ± 1.6 cm, while the 
calf circumference decreased by 3.6 ± 1.8 cm (Table 2); the 
rate of detumescence was up to 75%. The mean hospital 
stay was 11.3 days (range: 7-15 days). The mean hospital 
expense was $9,000 (range: $5,300-11,000).
Overall, there was an immediate technical success rate of 
81% (90 of 112) and a clinical success rate of 96% for the 
treated limbs. The treatment outcomes are listed in Table 3.
Complications
During the hospital stay, 14 (13%) patients experienced 
minor bleeding, of which bleeding at the puncture site 
occurred in 10 (9%) patients, and four (4%) patients had 
mucosal bleeding (2 cases of hematuria, 1 vaginal bleeding 
and 1 nose bleeding). Forty-one (37%) patients complained 
of slight pain in the affected knees (intramuscular 
hemorrhage or hemarthrosis was excluded by ultrasound 
and X-ray examination). None suffered from intracranial 
hemorrhage, symptomatic pulmonary embolism or other 
procedure-related complications.
Clinical Follow-Up
The average duration of follow-up was 15.2 months (range: 
3-24 months). During the period, the vein was patent in 
74 (67%) limbs, including 23 with stent placement. The 
overall stent patency was 92% (23 of 25); 37 (32%) limbs 
showed progression of the stenosis with luminal narrowing 
more than 50%, including three limbs with rethrombosis, 
four with PTA alone and two with stent placement, while 
asymptomatic iliac vein occlusion occurred in one limb 
with PTA alone. Twenty fi  ve (22%) limbs developed mild 
PTS that mainly presented as heaviness and edema of 
the affected limbs after activities, and mild pruritus or 
hyperpigmentation was also present in fi  ve limbs, but none 
of these fi  ve limbs had severe PTS. The median total PTS 
score was three (range: 0-9) and 52 limbs (47%) had a 
score of 0. Valvular refl  ux occurred in 24 (21%) limbs (Table 
4).
DISCUSSION
Systemic thrombolysis requires the thrombolytic agents to 
reach the position of the thrombus with blood fl  ow through 
open veins to bring the thrombolytic agents into the play, 
Table 3. Treatment Outcomes (112 Limbs in 110 
patients)
Variable Value 
Duration of CDT, hours 
  (mean, range) 
   196 (96-272)
Dose of urokinase, million IU 
  (mean, range) 
    3.5 (1.8-5.7)
Adjunctive procedures 
  PTA  5 (4%)
  PTA and stent  25 (22%)
Venous recanalization 
  Complete 31 (28%)
     PTA  0
     PTA and stent  15 (14%)
Partial 59  (53%)
     PTA  4 (4%)
     PTA and stent  10 (9%)
Minimal 22  (19%)
     PTA  1 (1%)
     PTA and stent  0
Bleeding complications * 14 (13%)
  Minor (A) 5 (5%)
  Minor (B) 9 (8%)
  Major (C-F) 0
Symptomatic pulmonary embolism  0
Technical success  90/112 (81%) 
Clinical success  108/112 (96%)
Duration of hospitalization, days 
  (mean, range) 
11.3 (7-15)
Expense of hospitalization, dollars 
  (mean, range)
9000 (5300-11,000)
Note.— CDT = catheter-directed thrombolysis, PTA = 
percutaneous angioplasty
*Complications were classifi  ed according to scoring system of 
Society of Interventional Radiology (SIR) (6, 7): Minor: A. No 
therapy, no consequence, B. Nominal therapy, no consequence, 
includes overnight admission for observation only; Major: 
C. Required therapy, minor hospitalization (< 48 hours), D. 
Required major therapy, unplanned increase in level of care, 
prolonged hospitalization (> 48 hours), E. Permanent adverse 
sequelae, and F. Death.Korean J Radiol 12(1), Jan/Feb 2011 www.kjronline.org 104
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and the thrombolytic effect declines greatly when the 
venous outfl  ow is obstructed (15). CDT involves a focused 
delivery of thrombolytic agents directly through the side 
holes of a catheter traversing the thrombus and this may 
be more effective for local thrombolysis and restoration of 
patency (16). But for a thrombus tending to adhere and 
organize after the acute stage, the current CDT with high-
dose thrombolytic agent administration in a short time 
(e.g., a mean of 7.8 million IU urokinase was administrated 
over an average of 51 hours at 100,000-370,000 IU/hour 
[3]) is usually not suffi  cient for non-acute DVT, and such 
administration has the potential for a higher bleeding rate. 
This study used CDT with a continuous infusion of low-
dose urokinase to treat non-acute lower extremity DVT. The 
mean infusion time (196 hours) was longer than that of a 
previously reported data (mean: 51 hours, range: 30-192 
hours) (3), and the average urokinase dose was 3.5 million 
IU as compared to the average dose of 7.8 million IU 
reported in Mewissen’s report (9). By the end of treatment, 
81% of the infusions achieved signifi  cant recanalization of 
≥ 50%, of which 28% achieved complete recanalization. 
During the mean 15.2 months of follow-up, the veins were 
patent in 74 (67%) limbs. Mewissen reported 36 (68%) 
infusions via CDT achieved signifi  cant recanalization in 
53 limbs with “chronic” DVT with a duration of symptoms 
more than 10 days, of which 19% of the limbs achieved 
complete recanalization; for all the infusions, the primary 
patency rate was 60% at one year (9). In general, an acute 
thrombotic event in a patient without a history of DVT will 
most likely yield a favorable grade of lysis, which in turn 
will be predictive of continued patency. CDT should only be 
proposed when DVT has occurred less than 10 days from the 
time lytic therapy is available (9), but our results showed 
that CDT with continuous infusion of low-dose urokinase 
could also be applied to non-acute DVT. Thus, the inclusion 
window for the symptom duration in our study (15-38 days) 
was wider than that in the previous studies (≤ 14 days) (17, 
18).
Because CDT alone does not always succeed in completely 
restoring venous patency, performing adjunctive procedures 
is common. These additional methods further diminish the 
clot burden and improve venous fl  ow. This study combined 
CDT with PTA or/and stent placement for residual stenosis. 
The results showed that the effect of PTA alone was not 
desirable. After PTA, the stenotic vein often soon recoiled 
and stent placement could generally prevent that. During 
follow-up, the overall stent patency was 92% (23 of 25); 
however, all the fi  ve cases that received PTA alone 
developed restenosis or occlusion in the iliac veins, and this 
result was in accordance with that of the previous studies 
(19-21). So we also suggest stent placement in the iliac 
vein rather than angioplasty only.
In this study, most patients reported symptom relief 
with decreased swelling and pain and improvement of 
the limb status: the detumescence rate was up to 75%. 
But it deserves noting that in some patients, the degree 
of thrombolysis was not satisfactory whereas the clinical 
symptoms were obviously alleviated, which might be related 
to re-opening of the intravenous collaterals.
Urokinase is a kind of plasminogen activator that is 
given at the time of thrombolysis, and this drug can 
cause accentuation of the fi  brinolytic system with a 
potential hemorrhagic risk. A higher incidence of bleeding 
is associated with using high-dose urokinase (22, 23). 
Mewissen et al. (9) reported on 473 DVT patients who were 
treated with catheter-directed urokinase (mean dose: 7.8 
million IU) for a mean of 53.4 hours and they achieved 
favorable venous patency, yet bleeding complications were 
reported in 27% (131 of 473) of the patients and 11% 
Table 4. Clinical Follow-Up Outcomes (n = 112)
Variable Value 
Follow-up duration, months (mean, range) 15.2 (3-24)
Venous patency
  Patent 74 (67%)
     PTA  0
     PTA and stent  23 (21%)
  Stenosis 37 (32%)
     PTA  4 (4%)
     PTA and stent  2 (2%)
     Rethrombosis 3 (3%)
  Occlusion 1 (1%)
     PTA  1 (1%)
     PTA and stent  0
Valve function
  Normal 88 (79%)
  Refl  ux 24 (21%)
Post-thrombotic syndrome
  No 87 (78%)
  Mild 25 (22%)
  Severe 0
Note.— PTA = percutaneous angioplastyKorean J Radiol 12(1), Jan/Feb 2011 www.kjronline.org 105
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(54 of 473) experienced major bleeding (9) that might 
have been related to a large dose of urokinase infused in a 
short time. In our study, CDT was characterized by a lower 
dose infusion for a longer time, and the venous patency 
we achieved was similar to that in Mewissen’s report, but 
the incidence of minor bleeding was only 13% (14 of 112) 
without any major hemorrhages. The bleeding complication 
rate was also obviously lower than the 30% in a review 
of the previous pooled data (24). In addition, 41 (37%) 
patients complained of slight pain in the affected knees 
during CDT (intramuscular hemorrhage or hemarthrosis was 
excluded by ultrasound and X-ray examination), but the 
pain disappeared after the patients performed moderate 
exercise after removal of the catheters and the sheaths, and 
so this pain might have been related to limited mobility of 
the knee-joint. 
When performing an endovenous operation, what needs to 
be stressed is that the operation should be done as gently 
as possible to reduce damage to the vein endothelium and 
valves and to avoid thrombus falling off due to the catheter 
or other apparatus. Placement of an IVC fi  lter may prevent 
fatal pulmonary embolism due to venous return. However, 
some scholars think that fi  lter placement is not associated 
with a reduced incidence of symptomatic pulmonary 
embolism (25). In this study, none of the patients suffered 
from symptomatic pulmonary embolism, including the 28 
patients who didn’t receive IVC fi  lter placement. However, 
physicians should be aware that pulmonary embolism is 
a serious complication that can cause death, and so an 
endovascular operation must be normative and gentle. 
With the fi  ndings of free-fl  oating thrombus in veins, we 
strongly recommend placement of an IVC fi  lter prior to the 
operation.
Post-thrombotic syndrome is a chronic condition 
characterized by leg edema, pain, varicose veins, skin 
induration and venous leg ulcers (26). It develops in 20-
50% of the patients within one to two years after the 
development of symptomatic DVT, of which fi  ve to 10% 
of these patients will develop severe PTS (27, 28). In our 
study, 25 (22%) patients suffered from mild PTS with the 
main manifestations of limb heaviness and edema after 
activities and none of them had severe PTS; valvular refl  ux 
occurred in 21% of the limbs in our study as compared to 
37% (39 of 106) at one year in Markel’s report (29). This 
refl  ects the ability of CDT to effectively preserve valve 
function and protect against the development of PTS. We 
presumed that the mechanism for this might be related to 
urokinase inhibiting the thrombus-induced infl  ammatory 
response through reducing the cytokines and adhesion 
molecules in the venous wall along with thrombus clearance 
and recanalizing veins, which in return maintained the 
functional integrity of the venous endothelium and smooth 
muscle cells (30). But it is suggested that careful long-term 
surveillance of the venous function is highly recommended 
after performing CDT.
In conclusion, our study results showed that CDT with a 
continuous infusion of low-dose urokinase was effective 
in removing the clot burden and restoring the venous 
fl  ow for the patients with non-acute lower extremity 
DVT, and our method reduced the incidence of bleeding 
complications and resulted in desirable mid-term outcomes. 
To a certain degree, the therapy extended the time window 
of thrombolysis therapy, but the drawback was the longer 
hospital stay and the higher expense. 
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